In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis
By integrating in vitro and clinical findings, we demonstrate that efgartigimod modulates peripheral immune cell populations, highlighting its significant immunomodulatory effects and clinical potential.
Authors
- Lei Jin (ORCID: https://orcid.org/0000-0002-9052-4590)
- Dingxian He (ORCID: https://orcid.org/0009-0005-9955-7179)
- Ming Guan (ORCID: https://orcid.org/0000-0002-8796-2653)
- Jianying Xi (ORCID: https://orcid.org/0000-0003-1028-3801)
- Sushan Luo (ORCID: https://orcid.org/0000-0002-9033-7568)
- Chongbo Zhao (ORCID: https://orcid.org/0000-0002-0475-1798)
- Ying Wang (ORCID: https://orcid.org/0000-0001-5623-4605)
- Dong Liu (ORCID: https://orcid.org/0000-0002-5109-9093)
- Yu Shi (ORCID: https://orcid.org/0000-0001-8878-1806)
- Chong Yan (ORCID: https://orcid.org/0009-0009-1451-3388)
- Jie Song (ORCID: https://orcid.org/0000-0002-3267-8348)
- Haoqin Jiang
Institutions
- Fudan University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1002/acn3.70283
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Shanghai Hospital Development Center
- National Key Research and Development Program of China